The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

BACKGROUND. On October 25, 2012, a conditional marketing authorization valid throughout the European Union (EU) was issued for brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) and for the treatment of adult patients with relapsed or refr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Gravanis, Iordanis, Tzogani, Kyriaki, van Hennik, Paula, de Graeff, Pieter, Schmitt, Petra, Mueller-Berghaus, Jan, Salmonson, Tomas, Gisselbrecht, Christian, Laane, Edward, Bergmann, Lothar, Pignatti, Francesco
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2016
Schlagworte:
Regulatory Issues: EMA
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4709212/
https://ncbi.nlm.nih.gov/pubmed/26621039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0276
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge